Characterization of the GSK-3beta protein and methods of use thereof
    3.
    发明申请
    Characterization of the GSK-3beta protein and methods of use thereof 审中-公开
    GSK-3β蛋白的表征及其使用方法

    公开(公告)号:US20080004433A1

    公开(公告)日:2008-01-03

    申请号:US11879719

    申请日:2007-07-18

    IPC分类号: C07K14/00 C07K1/00 G06G7/48

    摘要: The invention provides the three-dimensional structure of a construct of glycogen synthase kinase 3 (GSK3); crystals of a construct of glycogen synthase kinase 3-β (GSK3-β) containing the protein's catalytic kinase domain; a method for crystallizing the protein construct to provide a GSK3 crystal sufficient for structure determination; and a method for using the GSK3 construct's three-dimensional structure for the identification of possible therapeutic compounds in the treatment of various disease conditions mediated by GSK3 activity.

    摘要翻译: 本发明提供了糖原合酶激酶3(GSK3)构建体的三维结构; 含有蛋白质催化激酶结构域的糖原合成酶激酶3-β(GSK3-β)构建体的晶体; 使蛋白质构建体结晶以提供足以进行结构测定的GSK3晶体的方法; 以及使用GSK3构建体的三维结构来鉴定可能的治疗化合物以治疗由GSK3活性介导的各种疾病状况的方法。

    Indazole benzimidazole compounds
    4.
    发明申请
    Indazole benzimidazole compounds 失效
    吲唑苯并咪唑化合物

    公开(公告)号:US20060079564A1

    公开(公告)日:2006-04-13

    申请号:US11261995

    申请日:2005-10-27

    IPC分类号: A61K31/4184 C07D403/04

    CPC分类号: C07D403/04

    摘要: Organic compounds having the structure I are provided where the variables have the values described herein. A method of inhibiting c-ABL in a patient includes administering an effective amount of a compound of structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable salt of the tautomer to the patient.

    摘要翻译: 提供具有结构I的有机化合物,其中变量具有本文所述的值。 抑制患者中c-ABL的方法包括向患者施用有效量的结构I化合物,化合物的互变异构体,化合物的药学上可接受的盐或互变异构体的药学上可接受的盐。